Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Medical Countermeasure Program Among Senate Funding Priorities

Executive Summary

FDA should spend $19 million of an increase in non-user fee funding in fiscal 2012 on the agency’s medical countermeasures effort, the Senate Appropriations Committee recommends in the report that accompanies the Agriculture/FDA appropriations bill approved by the panel Sept 8.
Advertisement

Related Content

ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
FDA/CMS Data Sharing Encouraged In Senate Appropriations Report
Senate Wants FDA Plan To Speed Obesity Drug Development
FDA’s Funding Outlook Is Relatively Sunny, But Best For Growing Food
FDA’s Funding Outlook Is Relatively Sunny, But Best For Growing Food
First FDA Center Of Excellence For Regulatory Science Looks At Nanotechnology
Adjuvanted Flu Vaccines Get Booster: House Report Presses FDA On Approval
Speedy Vaccine Production Among Goals Of FDA's Budget Proposal For Countermeasures
FDA Dependence on User Fees Would Increase Under FY 2012 Budget Request
FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less

Topics

Advertisement
UsernamePublicRestriction

Register

PS053758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel